BRAF and Miyoshi myopathy: Molecular testing to determine BRAF mutation status has therefore become standard-of-care in the modern clinical management of patients with advanced MM, being currently the only available biomarker that can predict therapeutic responses to treatments with combined BRAF and MEK inhibitors.